Prostaglandin Reductase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prostaglandin reductase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prostaglandin Reductase Today - Breaking & Trending Today

The End of Pancreatic Cancer Could Be Just Around the Corner

Preclinical data showed that LP-184 shrunk tumors in vivo by more than 90% in just 8 weeks. ....

United States , Treasure Island , Temple University , Fox Chase Cancer Center , Igor Astsaturov , Paulf Engstrom , American Cancer Society , Temple University Health System , Current Options , Pancreatic Cancer Treatment Don T , Potential End , Lantern Pharma , American Cancer , Statpearls Publishing , Prostaglandin Reductase , Synthetic Lethal , Pancreatic Cancers , Mol Cancer , Pancreatic Cancer With Drug Candidate ,

Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary
RADR
® artificial intelligence ( A.I. ) platform to transform oncology drug discovery and development, today announced a collaboration with Johns Hopkins Pediatric Oncology Division of The Sidney Kimmel Comprehensive Cancer Center and Dr. Eric Raabe, M.D., Ph.D. focused on Lantern s drug candidate LP-184 in the area of brain tumors, and specifically in
Atypical
Rhabdoid
Tumors ( ATRT ), an ultra-rare and fast-growing cancerous tumor of the brain that presents primarily in children.
As we enriched our
RADR
® A.I. platform for additional cancer indications, we began to discover common molecular pathways that drive response to our drug candidate, LP-184, across multiple additional CNS cancers, stated Panna Sharma, President and CEO of Lantern Pharma. Chief among these newly identified CNS cancers was ATRT, an ultra-rare and fast-growing cance ....

United States , Marek Ciszewski , Eric Raabe , Johns Hopkin , Division Of Pediatric Oncology At Johns Hopkins , Exchange Commission On , Oncology Consortium , Johns Hopkins Pediatric Oncology Division , Oncology Drug Development Pipeline , Lantern Pharma Inc , Securities Exchange , Sidney Kimmel Comprehensive Cancer Center , Lantern Pharma , Atypical Teratoid Rhabdoid Tumors , Panna Sharma , Pediatric Oncology , Johns Hopkins , Pacific Pediatric Neuro Oncology , Rare Pediatric Disease , Rare Pediatric Disease Designation , Rare Pediatric Disease Priority Review Voucher , Prostaglandin Reductase , Securities Act , Securities Exchange Act , Risk Factors , Annual Report ,